<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00934219</url>
  </required_header>
  <id_info>
    <org_study_id>TgLL8506</org_study_id>
    <nct_id>NCT00934219</nct_id>
  </id_info>
  <brief_title>Triglyceride Lowering Study</brief_title>
  <acronym>TGLL</acronym>
  <official_title>Dose Related Decrease in Triglycerides in Patients With Hypertriglyceridemia and Treated With Lovaza.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jewish Hospital, Cincinnati, Ohio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jewish Hospital, Cincinnati, Ohio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lovaza is a special fish oil concentrate, that prescribed at 4 g a day to reduce certain fat
      (triglycerides) levels in blood.Our goal is to study how Lovaza at doses of 4, 8, and 12
      grams per day will reduce fats in the blood of the patients with very high level of
      triglycerides. Our hypothesis is that patients with very high triglycerides will respond more
      with higher doses of Lovaza (8 g per day and then 12 g per day).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lovaza contains Omega-3 fatty acids, the family of poly- unsaturated fatty acids. Omega-3
      fatty acids stimulate blood circulation, increases the breakdown of fibrin, and additionally
      has been shown to reduce blood pressure, cardiac events and mortality from congestive heart
      failure. There is strong scientific evidence that omega 3 fatty acids significantly reduce
      blood triglyceride levels while elevating high density lipoprotein cholesterol (HDL) levels.
      Fasting and non fasting hypertriglyceridemia have been associated with atherosclerosis, and
      coronary heart disease events, even in the absence of hypercholesterolemia. Severe
      hypertriglyceridemia (&gt;2000 mg/dl) can also lead to acute hemorrhagic pancreatitis.

      Currently, patients having very High TG are treated with Fibric acids (gemfibrozil, Tricor,
      Antara), and if hyperinsulinemic, with Glucophage. Lovaza (4g/day) has been shown to be
      effective and safe in lowering TG levels. There is no published data which indicates that
      Lovaza 8 or 12 g per day would have therapeutic effectiveness in further normalizing
      triglycerides in subjects on maximized triglyceride lowering and Lovaza 4 g per day. We
      hypothesize, based on our clinical experience that increasing Lovaza to 8 and then (if
      necessary) to 12 g/day would safely optimize triglycerides in subjects with primary
      hypertriglyceridemia who failed to normalize their triglycerides on optimal therapy including
      Lovaza 4 g/day.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>triglycerides level</measure>
    <time_frame>7 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>High dose Lovaza</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lovaza 4 g twice a day, if not effective then 4 g 3 times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 g twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3-Acid Ethyl Esters</intervention_name>
    <description>LOVAZA, 1 g caps; High Dose Arm for 4 months, while on a standard therapy for hypertriglyceridemia (fibrates, +/-metformin). Standard Dose Arm for 3 months, while on a standard, unchanged therapy for hypertriglyceridemia (fibrates +/- metformin).</description>
    <arm_group_label>High dose Lovaza</arm_group_label>
    <arm_group_label>Standard Dose</arm_group_label>
    <other_name>LOVAZA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Primary hypertriglyceridemia with fasting TG levels &gt;1000 mg/dl, and persistence of TG
             levels &gt; 500 mg/dl despite maximal TG lowering therapy for 1 month, including Lovaza 4
             g/day, fibric acids, and, where indicated, Glucophage for treatment of
             hyperinsulinemia.

          2. Patients with mild to moderately impaired renal function should be initiated on TRICOR
             48 mg and patients with severe renal impairment should not be given TRICOR.

          3. Absence of exclusionary criteria (see below).

        Exclusion Criteria:

          1. Patients with known allergy to fish

          2. Hypertriglyceridemia secondary to alcoholism, exogenous estrogens, nephrotic syndrome,
             hemochromatosis, glycogen storage disease, uncontrolled diabetes, exogenous
             corticosteroids, Cushing's syndrome, uremia).

          3. Bleeding gastric or duodenal ulcers, active inflammatory bowel disease.

          4. Pregnancy

          5. Dementia

          6. Patients with bleeding diatheses

          7. Patients who are taking concomitant anticoagulants and other medications that affect
             bleeding time (e.g., warfarin, aspirin)

          8. Patients with significantly abnormal transaminases (above 3x of upper normal limit)or
             any history of liver disease

          9. Patients with conditions affecting the skin (e.g. malignancy, vasculitides) that may
             confound the skin exam.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Glueck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>JEWISH HOSPITAL CHOLESTEROL CENTER</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LUANN SIEVE</last_name>
    <phone>(513)585-7951</phone>
    <email>luann.sieve@healthall.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Naila Goldenberg, MD</last_name>
    <phone>(513) 585-7950</phone>
    <email>naila.goldenberg@healthall.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jewish Hospital Cholesterol Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.jewishhospitalcincinnati.com/cholesterol/Research/FREE_TRIGLYCERIDE_LOWERING_STUDY-2009.html</url>
    <description>Free Triglycerides lowering study</description>
  </link>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2009</study_first_submitted>
  <study_first_submitted_qc>July 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2009</study_first_posted>
  <last_update_submitted>July 7, 2009</last_update_submitted>
  <last_update_submitted_qc>July 7, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2009</last_update_posted>
  <responsible_party>
    <name_title>Charles Glueck, MD Medical director of Cholesterol Center</name_title>
    <organization>Jewish Hospital Cholesterol Center</organization>
  </responsible_party>
  <keyword>hypertriglyceridemia</keyword>
  <keyword>triglycerides</keyword>
  <keyword>familial hypertriglyceridemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

